Pfizer reported lower third-quarter profit as demand for its Covid-19 vaccine and antiviral drug continue to decline. ...

格隆汇11月4日｜辉瑞(PFE.US)盘前涨超2%。消息面上，辉瑞第三季度营收166.5亿美元，预估165.9亿 美元；调整后每股收益0.87美元。辉瑞仍然预测全年营收610亿美元至640亿美元。预计全年调整后每股 收益3-3.15美元，此前预计2.9-3.1美元。 ...

Exhibit 99 Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance NEW YORK, Tuesday, November 4, 2025 — Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising and narrowing guidance for Adjusted diluted EPS. (1) (2) EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "I am proud of Pfizer's leadership as the first in our industry to reach an agreement with the U.S. Government, whic ...

Pfizer on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year profit guidance, as cost cuts helped to outweigh declining sales for the period fell.Here's what the company reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:Earnings per share: 87 cents adjusted vs. 63 cents expectedRevenue: $16.65 billion vs. $16.58 billion expectedThe results come weeks after Pfizer became the first drugmaker to str ...

市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何 意见、观点或结论是否符合其特定状况。据此投资，责任自负。 辉瑞第三季度调整后每股收益0.87美元。 辉瑞仍然预测全年营收610亿美元至640亿美元。 辉瑞预计全 年调整后每股收益3-3.15美元，此前预计2.9-3.1美元。 辉瑞美股盘前涨逾2%。 风险提示及免责条款 ...

Pfizer lifted its full-year profit forecast for the second time in a row on Tuesday, buoyed by strong demand for its blockbuster heart treatment and blood thinner. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Nov 4, 2025 6:45 AM Eastern Standard Time Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance Share NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising and narrowing guidance for Adjusted diluted EPS. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "I am proud of Pfizer's leadership as the first in our industry to reach an agreement with the U.S ...

市场表现 - 美国股票期货市场表现疲软 呈下跌态势 [1] 即将发布财报的公司 - 超微公司即将公布业绩 [1] - 优步公司即将公布业绩 [1] - 辉瑞公司即将公布业绩 [1] - 汤森路透公司即将公布业绩 [1]

2025.11. 04 本文字数：1535，阅读时长大约2分钟 作者 | 第一财经 钱童心 当地时间11月3日，美国制药公司辉瑞对丹麦制药公司诺和诺德提起第二起诉讼，指控诺和诺德试图以高于辉瑞的出价收购减重药厂商Metsera公司构成 反竞争行为。 辉瑞在当天提交给美国特拉华州地方法院的诉讼文件中还指控Metsera公司的控股股东与诺和诺德串通，试图影响新药的研发进程。 上周五，辉瑞已经请求特拉华州法院发布临时禁制令，以阻止Metsera终止与辉瑞之间的协议。 辉瑞声称，诺和诺德的出价并非真正为了收购Metsera的药物研发管线，而是一种战略策略，目的是维护目前司美格鲁肽的市场份额。 辉瑞还诉讼指控诺和诺德在监管审查之前就向Metsera股东提供65亿美元的预付款，并提出限制性条款，从而延迟或阻止新药的临床进展。 对此，诺和诺德负责媒体关系的全球副总裁Ambre James Brown在一份声明中表示："辉瑞公司声称诺和诺德打算通过收购要约来压制创新，这种说法 毫无根据，纯属捏造。" 她进一步指出，辉瑞没有在价格上进行竞争，而是采取了"极其不寻常且看似孤注一掷的方式"，提起了反垄断诉讼。诺和诺德的收购要约，包 ...